Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CL-Pola-R-CHP in Double/Triple-hit DLBCL
NCT07552324Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat and lisaftoclax in diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Primary endpoint: Complete Remission Rate. Planned start May 2026; status: not yet recruiting.
02
Drugs
tucidinostatlisaftoclax
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07552324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07552324.